Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

ID Number 11-0294

Principal Investigator(s)
Matthew Galsky

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to see the safety and effectiveness of Everolimus when given alone or when given in combination with Paclitaxel. Paclitaxel is the standard treatment that is routinely given to patients with your condition. Everolimus is an investigational drug, which means that is not approved by the FDA for the purpose of treating your type of cancer.

You may qualify to take part in this research study because you have a type of cancer called transitional cell carcinoma. Transitional cell carcinoma is a type of cancer that is usually from the bladder, but can also be from organs associated with the bladder, such as the ureters (tubes connecting the bladder with your kidneys).  In this consent form, we will refer to your cancer as TCC (which stands for transitional cell carcinoma).

Contact Information

Recruiting Patients: No